Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetes: later-stage trial registry
86 of 342 indexed Diabetes trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #19 of 28,707 conditions by registered trial count.
342 US clinical trials · 86 currently recruiting · #19 of 28,707 conditions by registered trial count
Diabetes: 342 US clinical trials tracked, 86 recruiting.
Diabetes is the subject of 342 registered US clinical trials on ClinicalTrials.gov, 86 of them currently open to new participants. 55 are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 41 of these trials.
Enrollment posture brief
Registry condition diabetes
OPEN 86 | RECR 25% | LATE 55 | EARLY 36 | RANK #19 | SPON 41
Volume-matched condition peers
Nearest open-share peer: Low Back Pain (25% recruiting · 123 trials)
Diabetes lists 86 open slots (25% of 342 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetes is recruiting below its size-band peers.
86 of 342 indexed trials (25.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetes trials is spread across many organizations.
Novo Nordisk A/S accounts for 41 of 342 trials (12%). 161 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetes enrolment sits around 150 participants.
Median target enrolment is 150 among the 339 trials that report a genuine target (sentinel values excluded). 144 of those (42.5%) plan for fewer than 100 participants.
-
Diabetes research is mostly interventional.
263 interventional and 79 observational studies make up this index (76.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
342 total, page 3 of 7
Insulin Balanced Infusion System
Admetsys Corporation
NCT01291719
REsearching Covid-19 Outcomes in Diabetes (RECODE)
AdventHealth Translational Research Institute
NCT04805970
Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices
M.D. Anderson Cancer Center
NCT05124405
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02262806
Patient Specific 3D Printed Diabetic Insoles to Reduce Plantar Pressure
VA Office of Research and Development
NCT05301478
CharacterIzation of Adult Onset Autoimmune Diabetes
AdventHealth Translational Research Institute
NCT03971955
I Can Do This! Managing My Diabetes
Emory University
NCT06695533
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02262832
Replication of the LEADER Diabetes Trial in Healthcare Claims
Brigham and Women's Hospital
NCT03936049
Replication of the EMPAREG Diabetes Trial in Healthcare Claims
Brigham and Women's Hospital
NCT04215536
Replication of the CARMELINA Diabetes Trial in Healthcare Claims
Brigham and Women's Hospital
NCT03936036
Effect of Reminders on Adherence
University of Pennsylvania
NCT02411006
Improving Service Delivery Through Access Points
US Department of Veterans Affairs
NCT00012623
Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants
Novo Nordisk A/S
NCT02608853
Environmental Polymorphisms Registry Health and Exposures Survey
National Institute of Environmental Health Sciences (NIEHS)
NCT01688986
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
Novo Nordisk A/S
NCT01959529
Cooking for Health Optimization With Patients
Tulane University
NCT03443635
INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study
Novo Nordisk A/S
NCT00101751
Adherence and Intensification of Medications (AIM) Implementation Study
US Department of Veterans Affairs
NCT00495794
Long Term Health Outcomes of Women Veterans' Service During the Vietnam Era
VA Office of Research and Development
NCT00958061
Diabetes in the Perioperative Period
Emory University
NCT00738114
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01336023
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
Novo Nordisk A/S
NCT03078478
Addressing Diffusion of Responsibility and Prescribing Burden to Improve Use of Diabetes Medications
Brigham and Women's Hospital
NCT05463705
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
Novo Nordisk A/S
NCT01836523
Family Management of Childhood Diabetes Study
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NCT00340938
"Working for You" Workplace Obesity Intervention
Washington University School of Medicine
NCT02934113
Insulin Treatment Variation in Southwestern Diabetics
VA Office of Research and Development
NCT00148304
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
Novo Nordisk A/S
NCT02648204
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
University of Virginia
NCT01369069
Study of a Holistic Health Program for United Methodist Clergy
Duke Clergy Health Initiative
NCT01564719
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
Novo Nordisk A/S
NCT02500706
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT02128932
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
Novo Nordisk A/S
NCT00972283
Improving Self Management Skills of Older Adults With Diabetes
Stanford University
NCT01943357
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
Eli Lilly and Company
NCT05362058
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
Novo Nordisk A/S
NCT01819129
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S
NCT02863328
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01885208
CARDIA Brain MRI Substudy
National Institute on Aging (NIA)
NCT01273311
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S
NCT02863419
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
Eli Lilly and Company
NCT05463744
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S
NCT00700817
The CREATE Wellness Study
Kaiser Permanente
NCT02302612
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01923181
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
Novo Nordisk A/S
NCT00982228
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01232491
Coalition for a Healthier Community-Utah Women and Girls - Phase II (UWAG-II)
University of Utah
NCT02470156
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
Novo Nordisk A/S
NCT00978627
NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
Novo Nordisk A/S
NCT00095446
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 13 |
| Phase 3 | 37 |
| Phase 4 | 18 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetes page
342 registered trials, 86 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 86 Diabetes trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novo Nordisk A/S sponsors the most Diabetes trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes condition card totals 342 registered trials; most-linked intervention insulin degludec; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.